Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets

doi:10.19803/j.1672-8629.20211034

Abstract

Abstract: Objective To optimize medication monitoring by clinical pharmacists and improve the role of therapeutic drug monitoring (TDM) via observation and follow-up of one case of adverse reactions caused by oral erlotinib. Methods Soon after one patient with lung cancer developed skin ulcer and corneal perforation following treatment with oral erlotinib, clinical pharmacists gave pharmaceutical care using evidence-based pharmacy and TDM. Results Through adjustment of the individualized medication regimen, symptomatic and supportive treatment of adverse reactions, the pain of the patient was significantly relieved, although her skin ulcer and corneal perforation were not cured. Conclusion In the course of medication for cancer patients, clinical pharmacists can use their expertise and knowledge to assist clinicians in providing individualized pharmaceutical care for patients, and contribute to rational clinical use of drugs.

Key words: erlotinib, skin ulcers, corneal perforation, adverse drug reaction, overexposure, blood concentration

CLC Number:

YUAN Qi, WANG Yingxian, CHEN Siying, YOU Haisheng. Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 206-208.

References

[1] PETIT AM, RAK J, HUNG MC, et al.Neutralizing antibodies againstepidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy ofsolid tumors[J]. Am J Pathol, 1997, 151(6): 1523-1530.
[2] ETTINGER DS, WOOD DE, AISNER DL, et al.NCCN guidelinesinsights: non-small cell lung cancer, version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[3] TAMURA M, TAKAI Y, NAKAMURA S, et al.A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis[J]. Acta Ophthalmol, 2020, 98(8): e1055-e1056.
[4] BRADEN RL, ANADKAT MJ.EGFR inhibitor-induced skinreactions: differentiating acneiform rash from superimposed bacterial infections[J]. Support Care Cancer, 2016, 24(9): 3943-3950.
[5] LACOUTURE ME.Mechanisms of cutaneous toxicities to EGFRinhibitors[J]. Nat Rev Cancer, 2006, 6(10): 803-812.
[6] OWCZAREK W, SŁOWIŃSKA M, LESIAK A, et al. The incidenceand management of cutaneous adverse events of the epidermal growth factor receptor inhibitors[J]. Postepy Dermatol Alergol, 2017, 34(5): 418-428.
[7] BORKAR DS, LACOUTURE ME, BASTI S.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review[J]. Support Care Cancer, 2013, 21(4): 1167-1174.
[8] CHOI HD, CHANG MJ.Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: a meta- analysis[J]. PLoS One, 2020, 15(7): e0234818.
[9] ENDO-TSUKUDE C, SASAKI JI, SAEKI S, et al.Population Pharmacokinetics and adverse events of erlotinib in japanese patients with non-small-cell lung cancer: impact of genetic polymorphisms in metabolizing enzymes and transporters[J]. Biol Pharm Bull, 2018, 41(1): 47-56.
[10] MUELLER-SCHOELL A, GROENLAND SL, SCHERF-CLAVELO, et al.Therapeutic drug monitoring of oral targeted antineoplastic drugs published correction appears in Eur J Clin Pharmacol[J]. Eur J Clin Pharmacol, 2021, 77(4): 441-464.
[11] LU JF, EPPLER SM, WOLF J, et al.Clinical pharmacokineticsof erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer[J]. Clin Pharmacol Ther, 2006, 80(2): 136-145.
[12] BIGOT F, BOUDOU-ROUQUETTE P, ARRONDEAU J, et al.Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old[J]. Investigational New Drugs: The Journal of New Anticancer Agents, 2017, 35(2): 242-246.
[13] NANNEY LB, MAGID M, STOSCHECK CM, et al.Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages[J]. J Invest Dermatol, 1984, 83(5): 385-393.
[14] CHARALAMBOUS A.Living with the effects of cutaneous toxicities induced by treatment[J]. Asia Pac J Oncol Nurs, 2017 , 4(3): 220-223.
[15] LIU Z, CARVAJAL M, CARRAWAY CA, et al.Expression ofthe receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in humanocularsurfaceepithelia[J]. Cornea, 2001, 20(1): 81-85.
[16] NA NNEY LB, STOSCHECK CM, KING LE JR, et al.Immunolocalization of epidermal growth factor receptors in normal developing human skin[J]. J Invest Dermatol, 1990, 94(6): 742-748.
[17] CIESKE JD, TAKAHASHI H, HUTCHEON AE, et al.Activation of epidermal growth factor receptor during corneal epithelial migration[J]. Invest Ophthalmol Vis Sci, 2000, 41(6): 1346-1355.
[18] PETERSON JL, CERESA BP.Epidermal growth factor receptor expression in the corneal epithelium[J]. Cells, 2021, 10(9): 2409.